TNFR2 Blockade Promotes Antitumoral Immune Response in PDAC by Targeting Activated Treg and Reducing T Cell Exhaustion

Scientists hypothesized that TNFR2 inhibition using a blocking monoclonal antibody could shift the Treg-effector T cell balance in pancreatic ductal adenocarcinoma, thus enhancing antitumoral responses.